* Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on i...
RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and prelimi...
– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a...